Poster Sessions

Friday, 13 December 2013

Friday | Saturday | top

12:30 - 13:30

Poster Session 1
Michigan Ballroom (Westin - Michigan Avenue)
 Chairperson: Michael Foggs (US)
1000
1000: Efficacy and Safety of Specific Sublingual Immunotherapy with Carbamylated Allergoid Tablets of Ragweed Pollen: A Dose-Ranging Study | Enrico Compalati (Italy)
1001
1001: ALLERGENIUS®: an Expert System for the Interpretation of Allergen Microarrays | G. Walter Canonica (Italy)
1002
1002: Galectin-3 as Predictive Biomarker of Airways Remodeling Modulation in Omalizumab Treated Severe Asthma Patients | G. Walter Canonica (Italy)
1003
1003: Omalizumab is Effective in Allergic and Nonallergic Patients | Claus Bachert (Sweden)
1004
1004: The Effect of B7-H3 on CD4+ T Lymphocyte Activation in Vitro | Jun Sik Lee (South Korea)
1005
1005: Analysis of the mechanism of the allergen immunotherapy in Japanese cedar pollinosis | Takenori Haruna (Japan)
1006
1006: Baicalin From Scutellaria baicalensis Impairs Th1 Polarization Through Inhibition of Dendritic Cell Maturation | Jun Sik Lee (South Korea)
1007
1007: Universal Allergen Particle Generation for Inhaled Allergen Challenges in the Fraunhofer Environmental Challenge Chamber (ECC) | Jens M Hohlfeld (Germany)
1008
1008: Dialyzable Leukocyte Extracts as Adjuvant Treatment for Allergic Rhinitis | Toni Angela Homberg (Mexico)
1009
1009: AAAAI Survey on Allergen Immunotherapy (AIT) in Patients withSpecific Medical Conditions | Désirée Larenas-Linnemann (Mexico)
1010
1010: AAAAI Membership Experience with Venom Immunotherapy in Chronic Medical Conditions, Pregnancy and Young Children | Désirée Larenas-Linnemann (Mexico)
1011
1011: Potential Immunogenetic Associations Between Atopy and Metabolic Syndrome In Children | Laura Vidal (Mexico)
1012
1012: Safety and Efficacy Of Omalizumab In 10 Children With Asthma and Other Allergic Comorbidities | Ana Célia Costa (Portugal)
1013
1013: IL-4R Alpha Antibody Inhibits IgE Production and Airway Remodeling In Mouse Model Of House Dust Mite-Induced Eosinophilic Asthma | Ludmila Kelly (United States)
1014
1014: Omalizumab Efficiency In Patients With Allergic Rhinitis and Chronic Sinusitis | Lorena Rangel-Garza (Mexico)
1015
1015: : A Semi-rational Approach to Obtain a Thermostable Ionic Liquid Tolerant Bacterial Laccase Through Π- Type Interactions | Farideh Ghazi (Iran)
1016
1016: A Novel Peanut Allergoid Is Safe and Effective In a Murine Immunotherapy Model For Peanut Allergy | Hans Van Schijndel (Netherlands)
1017
1017: Preclinical and Clinical Findings: Role Of Periostin, IL-13, Lebrikzumab and Corticosteroid Resistance | Robert Townley (United States)
1018
1018: Evaluation Of CCR3 As a Basophil Activation Marker | Aaruni Khanolkar (United States)
1019
1019: Novel Allergy Vaccine Delivery System For Poison Ivy Urushiol (PI) and Peanut (PN) | Robert Coifman (United States)
1020
1020: Efficacy and Safety Of Sublingual Specific Immunotherapy With Pru p 3 In a Portuguese Population - Clinical and Immunological Evaluation During 12 Months | Ana Célia Costa (Portugal)
1021
1021: Use Of Paper Filter Discs For Measurement Of Local Biomarkers Of Nasal Mucosal Inflammation | Margot Berings (Belgium)
1022
1022: Angioedema and Angioedema Management From Asteria II: A Clinical Trial To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Who Remain Symptomatic Despite H1 Antihistamine Treatment | James Zazzali (United States)
1023
1023: Dupilumab Suppresses Th2 Inflammation In Adult Asthma and Atopic Dermatitis | Brian Swanson (United States)
1024
1024: Accelerated Healing Of Full-Thickness Cutaneous Wound Using Purified Apitoxin From Asiatic Honey Bee (Apis cerana Fabricius) | Hua Chen (China)
1025
1025: Introduction To The Clinical Practice Of Molecular Allergology | Guy Tropper (Canada)
1026
1026: Randomized Clinical Trial to Evaluate Oral Dializable Leukocyte Extracts as Immunemodulator Treatment in Atopic Dermatitis | Jorge Galicia Carreón (Mexico)

Saturday, 14 December 2013

Friday | Saturday | top

12:00 - 13:00

Poster Session 2
Michigan Ballroom (Westin - Michigan Avenue)
 Chairpersons: João Tebyrica (Brazil) , Ruchi Gupta (US)
2000
2000: A Case Study in Effective Innovative Strategic Multi-modal Recruitment Strategies in Difficult-to-Recruit Patient Populations: Study of Safety and Tolerability of Novel SLIT in an Adolescent Population | Anne Marie Salapatek (Canada)
2001
2001: Generation a hypoallergenic profilin from Amaranthus palmeri pollen | CESAR Manuel Landa (Mexico)
2002
2002: Transfer Factor May Provide Immunomodulation In Cutaneous Tuberculosis | Laura Vidal (Mexico)
2003
2003: Cat-PAD, The First In a New Class Of Synthetic Peptide Immuno-Regulatory Epitopes, Demonstrates a Favourable Safety and Tolerability Profile In Patients With Cat-Induced Rhinoconjunctivitis | Roderick Peter Hafner (United Kingdom)
2004
2004: Bio Immun(G)En Medicine Or How To Link Scientific Research and Daily Therapeutic Practice | Gilbert Glady (France)
2005
2005: Application Of a Standardized Titrated Nasal Provocation Test With HDM and Birch Pollen Extract In Multicentre Clinical Studies In Allergic Rhinitis | Diderik Boot (Netherlands)
2006
2006: Fel d 1 Derived Synthetic Peptide Immune-Regulatory Epitopes Improve Nasal Symptoms Of Cat Allergy 2 Years After Administration Of 4 Doses Over a 12 Week Period | Roderick Peter Hafner (United Kingdom)
2007
2007: Treatment With Fel d 1 Derived Synthetic Peptide Immune-Regulatory Epitopes Results In a Persistent Treatment Effect On Symptoms Of Cat Allergy 2 Years After Treatment With 4 Doses 4 Weeks Apart | Roderick Peter Hafner (United Kingdom)
2008
2008: Sublingual RUSH Immunotherapy | Ramandra Nath Mitra (India)
2009
2009: Clinical Substantiation Of Immunocorrective Therapy In Children With Atopic Dermatitis | Tatiana Slavyanskaya (Russia)
2010
2010: A Study Assessing The Safety and Efficacy Of Subcutaneous Immunotherapy With a Dust Mite Vaccine With The Adjuvant L-Tyrosine In a Highly Sensitized Population In a Latin-American City | Jorge F Maspero (Argentina)
2011
2011: A DNA Vaccine Immunotherapy For Japanese Red Cedar Allergy | Lawrence Weiner (United States)
2012
2012: House Dust Mite Sublingual Immunotherapy With Standardized Vaccines: Prescription and Adverse Events | Alexander Diaz Rodriguez (Cuba)
2013
2013: The Safety Of The United Allergy Services Immunotherapy Protocol | Frederick Schaffer (United States)
2014
2014: A Survey Of Respiratory Physicians' Opinion Of SIT In Asthma Treatment In Wuhan Of China | Rongfei Zhu (China)
2015
2015: Quality Of Life Improvement With Sublingual Immunotherapy: A Prospective Study Of Efficacy | Mary S. Morris (United States)
2016
2016: The Effect and Value Of Sublingual Immunotherapy: A Patient Survey | Mary S. Morris (United States)
2017
2017: Molecular Profiles Of IgE To Timothy Grass Allergens In Patients Screened For Grass Tablet Immunotherapy | Hendrik Nolte (United States)
2018
2018: Efficacy and Safety Of Grass Sublingual Immunotherapy Tablet (SLIT-T) Treatment In a Large Randomized Controlled Trial In North American Children and Adults | Hendrik Nolte (United States)
2019
2019: Grass Sublingual Immunotherapy Tablet (SLIT-T) Treatment Is Associated With Similar Efficacy and Safety In Children and Adults: Subgroup Analysis Of Data From a Large North American Trial | Hendrik Nolte (United States)
2020
2020: Effect Of Sublingual Immunotherapy Tablet (SLIT-T) Treatment On Daily Medication Score Using Alternative Scoring Methods Based On WAO Recommendations | Hendrik Nolte (United States)
2021
2021: The Incidence Of Adverse Reactions Induced By Subcutaneous Immunotherapy In An Allergy Center In Monterrey, México: A Retrospective Chart Review | Lorena Rangel (Mexico)
2022
2022: Sublingual Immunotherapy In The Treatment Of Allergic Rhinitis: Series Of Cases | Lorena Rangel-Garza (Mexico)